Clinical trials: Internal Radiation, open to volunteers
- Condition Internal Radiation
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Glioblastoma
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: A Screening/Baseline Period of 21 days.
- Trial name
- BRIDGES (NCT07195591)
- Testing
- GammaTile®, External Beam Radiation Therapy, Temozolomide
- Where
- 20 sites in United States
- Volunteers
- 766 people
- Sponsor
- GT Medical Technologies, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
The goal of this clinical investigation is to learn if a new type of radiotherapy works to treat pancreatic cancer that cannot be removed surgically.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable
- Trial name
- NCT07155850
- Testing
- Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 10 people
- Sponsor
- BetaGlue Therapeutics SpA
Lung Cancer, Lung Cancer Stage I
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing…
- Conditions
- Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II
- Trial name
- NCT03290534
- Testing
- CivaSheet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CivaTech Oncology
Malignant Tumor
Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors
This study is a Compassionate clinical study for the treatment of Malignant Tumors. The primary endpoint of the study is to assess the frequency, severity and causality of acute adverse events related to the DaRT treatment.
- Trial name
- NCT05781555
- Testing
- Experimental: DaRT seeds
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Alpha Tau Medical LTD.
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
- Trial name
- NCT07589257
- Testing
- VRT106 for injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Recurrent Glioblastoma
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease.
- Trial name
- ODYSSEY (NCT07867886)
- Testing
- Device: TheraSphere GBM treatment of TheraSphere GBM device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Head and Neck Squamous Cell Carcinoma, Skin Cancer
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT05047094
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT), Pembrolizumab
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- Alpha Tau Medical LTD.
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China.
- Trial name
- NCT06712017
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Liver Metastases
Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases
This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases.
- Trial name
- NCT05829291
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Carcinoma of the Vulva, Recurrent Carcinoma of the Vulva
Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva.
- Trial name
- NCT06202339
- Testing
- DaRT seeds
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
Adjunct Episcleral Brachytherapy for PCV
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate…
- Trial name
- KILAUEA (NCT05251636)
- Testing
- Episcleral Brachytherapy, Aflibercept Injection
- Volunteers
- 159 people
- Sponsor
- Salutaris Medical Devices, Inc.
Pancreatic Cancer
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
- Trial name
- NCT02843945
- Testing
- Directional Brachytherapy Source Implant
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- CivaTech Oncology
Hepatocellular Carcinoma (HCC)
A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer.
- Trial name
- NCT07663487
- Testing
- SIR-Spheres Selectively Delivered to Liver Tumor
- Volunteers
- 78 people
- Sponsor
- Sirtex Medical
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreatic Neoplasm, Digestive System Neoplasm
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination…
- Conditions
- Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
- Trial name
- OSPREY (NCT04493632)
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 500 people
- Sponsor
- OncoSil Medical Limited
Recurrent Glioblastoma, Recurrent Gliomas
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
- Trial name
- NCT06910306
- Testing
- Device :DaRT seeds
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.